A New Warning for Patients
A wave of new research is highlighting a critical aspect of treatment with GLP-1 drugs like semaglutide and tirzepatide: the cardiovascular benefits they provide may quickly disappear once the medication is stopped. One recent observational study published
in The Lancet Regional Health Europe looked at over 80,000 people with type 2 diabetes in Italy. It found that those who discontinued their GLP-1 treatment had roughly double the risk of a heart attack, stroke, or death compared to those who continued the therapy. Specifically, the rate of these major events was about four per 100 people per year in the group that stopped, versus about two per 100 in the group that persisted with the medication. This finding suggests the protective shield these drugs offer the heart is not permanent and depends on continuous use.
What Are GLP-1 Agonists?
GLP-1 receptor agonists are a class of medications that have revolutionised the management of type 2 diabetes. They work by mimicking a natural hormone called glucagon-like peptide-1, which our bodies produce in the intestines. This hormone plays a key role in regulating blood sugar by stimulating insulin release and reducing glucagon, another hormone that raises blood sugar. It also slows down stomach emptying and signals to the brain that you are full, which reduces appetite and often leads to significant weight loss. Popular brand names include Ozempic, Wegovy, Mounjaro, and Zepbound. Beyond blood sugar control and weight loss, studies have consistently shown these drugs also provide powerful protection for the cardiovascular system.
The 'Rebound Effect' Explained
When a person stops taking a GLP-1 medication, they can experience what some call a 'rebound effect'. The most immediate and noticeable change is often a sharp return of appetite and food cravings. However, the changes are more than just hunger. Blood sugar levels can rise again, blood pressure can increase, and cholesterol levels can worsen. One senior researcher described this phenomenon as 'metabolic whiplash'. A study of U.S. veterans with type 2 diabetes found that stopping treatment was associated with a progressive increase in risk. After two years off the medication, patients had up to a 22% higher risk of heart attack, stroke, and death compared to those who stayed on the treatment, effectively erasing the benefits gained.
Why Do People Stop Treatment?
If continuous use is so important, why do so many people stop? The reasons are varied and complex. Side effects are a major factor; common issues like nausea, vomiting, and constipation can be troublesome enough for people to discontinue the drug. Cost and insurance coverage are other significant hurdles that force patients to stop. Some people also stop after reaching their weight loss or blood sugar goals, mistakenly believing the treatment is a short-term fix rather than a long-term management strategy for a chronic condition. Studies show that a large percentage of patients—in some cases over 60%—stop taking their GLP-1 medication within a year or two.
What This Means for Patients
The key takeaway from this growing body of research is that GLP-1 drugs should be viewed as a long-term therapy for a chronic disease, not a temporary solution. The heart-protective benefits are tied to ongoing use. While observational studies cannot prove that stopping the drug directly causes heart attacks, they reveal a strong and concerning link between discontinuation and increased risk. Experts stress that this doesn't mean the drugs are dangerous; rather, it highlights how effective they are when taken consistently. The decision to start, and especially to stop, a GLP-1 medication should not be taken lightly. It requires a thorough conversation with a doctor to weigh the benefits, risks, and the necessity of long-term commitment to maintain health gains.
















